The purpose of this observational study was to investigate the clinical merit of measuring plasma galectin-9 and CXCL-13 concentrations as predictors of CLL activity, prognosis, and early indicators of therapeutic response. Here, CXCL13 is linked to B-cell chronic lymphocytic leukemia.